IRON
Disc Medicine, Inc.
$68.26
+1.08%
2026-05-08
About Disc Medicine, Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
Key Fundamentals
Forward P/E
-8.90
EPS (TTM)
$-6.64
ROE
-35.8%
Profit Margin
0.0%
Debt/Equity
4.51
Price/Book
3.45
Beta
2.14
Market Cap
$2.57B
Avg Volume (10D)
386K
Recent Breakout Signals
No recent breakout signals detected for IRON.
Recent Price Range (60 Days)
60D High
$73.97
60D Low
$40.00
Avg Volume
595K
Latest Close
$68.26
Get breakout alerts for IRON
Sign up for Breakout Scanner to receive daily notifications when IRON triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Disc Medicine, Inc. (IRON) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors IRON daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. IRON operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.